Abstract: A reversible color-changing ink formulation, and a nonwoven wipe to which the ink formulation is securely bound, are provided. The reversible color-changing ink formulation includes about 55-98% by weight of a polymer binder, about 0.1-20% by weight of a reversible color-changing dye that reversibly changes between a first color and a second color at a pH of about 5.5 to about 8.0, and optional amounts of plasticizer, inorganic particulate filler, and color brightener. During use, the nonwoven wipe is impregnated with a sanitizer solution that contains a quaternary ammonium compound. The nonwoven wipe reversibly changes between a first color when impregnated with the sanitizer solution and a second color when the sanitizer solution is depleted during use. The change to the second color indicates the need to recharge the nonwoven wipe with the sanitizer solution, whereupon the first color returns.

Abstract: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse and optionally physiologically acceptable adjuvants. The invention also relates to a corresponding method for producing said dosage form.

Abstract: Disclosed herein are gustatory and/or olfactory aversion compositions comprising one or more bitterants and appropriate adhesives or tackifiers, and the like, which provide a long-lasting effect. The compositions are useful for behavior modification, especially in animals, such as pets or livestock.

Abstract: According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method.

Abstract: A method for labeling a UV-fluorescing substrate includes positioning a UV-fluorescing substrate adjacent to an inkjet material dispenser, and selectively jetting an edible, invisible, non-UV fluorescing ink onto the UV-fluorescing substrate with the inkjet material dispenser.

Abstract: A micronutrient supplement the supplement being characterized by having at least two types of distinct dosage units wherein said distinct dosage units which physically separate nutritional, vitamin or mineral supplements which are known or proven to be negatively interacting when co-mingled or co-administered, the distinct dosage units being designed to be taken at a predetermined time interval.

Abstract: A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid, and wherein the first part, the second part, or both the first and second parts comprise an olefin compound.

Abstract: An osteogenic composition is provided for implantation at or near a target tissue site beneath the skin, the osteogenic composition comprising a growth factor and a coloring agent, wherein the coloring agent imparts color to the growth factor to allow the user to see the growth factor at or near the target tissue site. In some embodiments, a method is provided for accelerating bone repair, the method comprising mixing bone morphogenic protein-2 and a coloring agent to form a mixture; applying the mixture to a surface of a porous collagen matrix, wherein the coloring agent allows the user to see bone morphogenic protein-2 distribution on or in the porous collagen matrix; and implanting the porous collagen matrix at or near a target tissue site in need of bone repair.

Abstract: A pharmaceutical dosage form is provided that has a distinguishing characteristic and an identifier associated with the dosage form. The distinguishing characteristic is assigned from a limited set of distinguishing characteristics and is determined upon oral administration of the dosage form, or is detected in breath, bodily fluids, or tissues after ingestion, or injection or other non-oral administration. The identifier is associated with the dosage form and with the distinguishing characteristic. The identifier is associated with only one distinguishing characteristic but the distinguishing characteristic may be associated with multiple identifiers. The pharmaceutical dosage form may be used in a method to monitor compliance with a dosage regimen.

Abstract: 1. Liquefied (or Liquified) Phenol USP (Carbolic Acid Liquefied) is Phenol maintained in a liquid condition by the presence of 10.0% water. Its topical medical use includes P & A (Phenol & Alcohol) procedures, and other procedures necessitating an anesthetic antiseptic, solvent, or cauterant. In treating ingrown nails, it is applied to the nail bed to prevent regrowth of nails. As a colorless solution, it can be difficult to see where an application is going during a procedure. Phenol with color eliminates this problem by creating a readily visible way of identifying where the application is going. 2. The patent calls for recognition of our innovation to mix Phenol with color for visual enhancement for physicians or others. “Phenol with color” is thus the innovation being patented and not the actual name of a product.

Abstract: A dosage form includes a dose of at least one bioactive agent and a substance that is visible to a normal light or to a special light source in the buccal, vaginal, rectal or ostomic cavity of a patient in order for medical personnel to determine if the patient is being compliant with taking medication or that a person is not truthful in denial of taking medication. The substance is either coating the at least one bioactive agent or intermixed with the at least one bioactive agent in a delivering body, and leaves behind a stain in the cavity for a predetermined period for compliance/abuse assessment.

Abstract: A composition comprising at least one indicator, at least one light stabilizer, and at least one antioxidant. The composition is useful as a cleanser that provides a usage timer based on color change to indicate to a person that sufficient time has elapsed for cleansing.

Abstract: Two-phase preparation for temporally gradual administration comprising a) a phase (A) comprising water soluble vitamins and/or the corresponding provitamins, wherein phase (A) does not contain liposoluble vitamins or provitamins corresponding to liposoluble vitamins, b) a phase (B) comprising vitamins and/or the corresponding provitamins, wherein the quantity of liposoluble vitamin compounds is larger than the quantity of water soluble vitamin compounds.

Abstract: According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method.

Abstract: According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method.

Abstract: Anti-viral tissues are provided with a pH indicator which provides the tissue user with a visual indicia, via color changes, that the tissue has active ingredients. Furthermore, the pH indicators can be used to illustrate neutralization of the pH of infected nasal discharge, which has a higher pH than healthy nasal discharge, giving the user a reason to believe that the product is working to deactivate virus.

Abstract: Anti-viral tissues are provided with a pH indicator which can communicate to a tissue user by means of visual indicia, via color changes, that the tissue has active ingredients. Furthermore, the pH indicators can be used to illustrate neutralization of the pH of infected nasal discharge, which has a higher pH than healthy nasal discharge, giving the user a reason to believe that the product is working to deactivate virus.

Abstract: According to the present invention, a vaccine or pharmaceutical-containing composition is applied to the muzzle area of the animal, which will then naturally use its tongue to clean itself. This behavior will cause the animal to deposit applied composition to the mucosa of the nasal and oral cavities, thus meeting the need for a simple, effective, and efficient vaccination or treatment method.

Abstract: A detergent and disinfectant in which water-soluble permanganates are used in an alkaline solution in order to initiate the oxidation of organic substances and simultaneously a chemical oxidant, preferably a peroxodisulfate, is used which is capable of producing radical reactions with catalytic support by manganates originating from the supplied permanganate, which reactions produce the oxidation of organic substances. All components are present in powder form and a respective powder mixture can be dissolved rapidly and free from residues in water. It thus represents a universally applicable, highly effective detergent and disinfectant.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Abstract: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.

Abstract: The invention is directed to biocide capsule for using it in a biocide preparation, wherein at least one active ingredient is enclosed in the capsules with a wall not dissolving, or dissolving only to a minimal extent in watery environment with a pH range below the cutting pH value, but dissolving in the pH-range over the cutting pH value, and at least one of the wall and the load contains an indicator substance suitable for colour indication. The invention is directed to the biocide preparation containing the vaginal treating substance and the capsules evenly distributed. The preparation is used for healthcare purposes, primarily for killing the pathogens of the body surface, body orifices, open and closed body cavities. The preparation can advantageously be used for the treatment and/or diagnosis of the vagina.

Abstract: Orally disintegrating tablets containing colored granules of a water-soluble sugar which give them a speckled appearance are described. The orally disintegrating tablets with speckled appearance are readily and easy identifiable by physicians, nurses and patients.

Abstract: This invention discloses a surgical prep solution formulation, either film forming or non-film forming, that changes color upon a change in pH to indicate that the solvent has sufficiently evaporated. The major components of this surgical prep solution include: antimicrobial agents, solvents, pH adjusters, color changing pH indicators, and optionally: film forming polymers, dyes and viscosity regulators. The pH of the solution may rise or fall depending on the pH of the original solution as compared with the normal pH range of the acid mantle of the human skin or the normal pH range of a sterilizing solution. As the pH changes, the pH indicator may cause the surgical prep solution to change color. Concurrently, as the fluids evaporate, the pH indicators interact with atmospheric CO2, causing the solution to change color based on the pH of the solution. The solution may also be used as coating for medical devices.

Abstract: A unit assembly including a plurality of individual film strips, each film strip having an active within a polymer matrix, the film strips having respective perimetrical edges, the plurality of individual film strips being alternatingly positioned next to one another such that a film strip perimetrical edge is at least partially offset from a subsequent film strip perimetrical edge, wherein the respective perimetrical edges of the film strips are directly adjacent to each other.

Abstract: Disclosed is a double-layered tablet containing zaleplon. The tablet includes an instant release layer and a delayed release layer. The instant release layer contains zaleplon, lactose, maltose, microcrystalline cellulose, sodium lauryl sulfate, and at least one excipient. The delayed release layer contains zaleplon, maltose, microcrystalline cellulose, a polymer, and at least one excipient. A dissolution curve is obtained for the double-layered zaleplon-contained tablet by using a 0.1N hydrochloric acid buffer and pH 6.8 phosphoric acid buffer contained in stirring devices having rotatable blades with stirring speeds of 50-200 RPM, and the release of zaleplon is controlled in such a way to follow the dissolution curve, so as to provide the advantages of improving sleep quality, enhancing safety of medicine use, being convenient to use, and offering flexible dosing.

Abstract: A formulation for topical application to human skin and other surface preparation compositions containing antimicrobial, antifungal and antiviral compounds which remain on human skin and other surface compositions to reduce or dominate bacteria, virus and fungi present, prevent future contamination by their presence and substantive character, contain agents or compounds that contain antibacterial, antiviral and antifungal properties and flourescent dyes and tracers that contain illumination properties exhibiting various colons including clear and no color pigment, that when exposed to certain light such as ultraviolet, will produce an illumination effect in various colors including dear and no color for a period of time within a preferred range of thirty minutes to six hours or longer from the time of initial application, and prior to for instance application of ultraviolet light, such flourescent dyes and tracers appear to be clear in color, invisible or have no color pigment showing on the skin or other sur

Abstract: There is provided a marking method that is highly productive and enables production of easily-identifiable compositions for use in oral administration such as drugs and foods without damaging the quality of the oral composition. The marking method according to the present invention is a method for marking such a composition for use in oral administration and includes the steps of: dispersing a change in color-inducing oxide in the composition for use in oral administration; and scanning a surface of the composition for use in oral administration with a laser beam at wavelengths of from 200 nm to 1100 nm and with from 0.1 W to 50 W average power in to make the particles of the change in color-inducing oxide agglomerate so as to become discolored. The change in color-inducing oxide used in the present invention is at least one selected from the group consisting of titanium dioxide, yellow ferric oxide, and red ferric oxide.

Abstract: A selected substance is dissolved into a given injectable fluid medication having an initial clear visual appearance. The selected substance is selected from a group of substances which, when dissolved in the injectable fluid medication, will alter the clear appearance to produce a non-clear or altered visual appearance. The altered visual appearance could be a color, which, by code, identifies the given injectable fluid medication, and distinguishes the given injectable fluid medication from a different injectable fluid medication, the clear visual appearance of which has been altered by dissolving another selected substance to produce a colored visual appearance different from the color of the altered visual appearance of the given injectable fluid medication.

Abstract: A selected substance is dissolved into a given injectable fluid medication having an initial clear visual appearance. The selected substance is selected from a group of substances which, when dissolved in the injectable fluid medication, will alter the clear appearance to produce a non-clear or altered visual appearance. The altered visual appearance could be a color, which, by code, identifies the given injectable fluid medication, and distinguishes the given injectable fluid medication from a different injectable fluid medication, the clear visual appearance of which has been altered by dissolving another selected substance to produce a colored visual appearance different from the color of the altered visual appearance of the given injectable fluid medication.

Abstract: A luminescent composition, with a luminescent marker and a ionizing agent exhibiting luminescence for an indicatory period once intermixed, and with luminance intensity remaining at a threshold intensity during indicatory period. Luminescence also can be exhibited responsive to responsive to excitatory light applied to the composition. The luminescent marker includes a coumarinic compound and the ionizing agent includes an ammonium base. Antimicrobial agents are included. A luminescence measuring apparatus includes a photoemitter and a photodetector responsive to an emissive light induced by photoemitter. An optical filter can be used with the photodetector. A two-phase composition dispensing apparatus includes a first phase reservoir, a second phase reservoir, a mixing nozzle, and a dispensing mechanism.

Abstract: The present invention relates to a coated dosage form having openings to expose the core material or an intermediate coating layer. The invention also relates to methods for manufacturing such coated dosage forms.

Abstract: A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation. In one embodiment, the concentrated esmolol formulation allows identification of the concentrate even after transfer of the concentrate out of a labeled primary container. The concentrated esmolol formulation can include from about 25 to about 1000 mg/ml of esmolol hydrochloride, a buffering agent and a color additive. Any number of color additives may be included such as indocyanine green, phenopheylene, hemoglobin, cyanocobalamine, patent blue, and indigo carmine vitamin B2 and naturally occurring vitamins and minerals. The amount included in the formulation is highly dependent on the color additive selected. The color additive should be included in an amount sufficient to easily distinguish the concentrated esmolol formulation from at least about a 1:4 dilution of the concentrate.

Abstract: The invention relates to a form of administration which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof.

Abstract: This invention relates to use of an opioid receptor agonist in microdose quantities to reduce or eliminate the withdrawal symptoms associated with discontinuing drug use. The dosage of the agonist is reduced over an extended period of time.

Abstract: Skin sealants are usually applied over skin preps to seal the skin and hold any remaining bacteria in place prior to surgical incisions. This sealant is generally left on the skin after surgery. A skin coating is provided that has an indicator that gives a visible color change upon contact with microbes or microbial by-products and so provides an early warning of infection. The coating is a curable coating composition that may also be used without skin preps and may be used to protect other disruptions in the skin like wounds, bruises, abrasions, burns, acne, blisters, bites, stings, punctures and cuts. It may also be used to close wounds or provide an additional barrier to other parts of the skin, such as the nails and mucosa.

Abstract: A sustained-release matrix for dental application includes either an anti-microbial agent or a colorant that is released from the matrix when the matrix contacts water. The preferred matrices include a water-soluble polymer and a water-insoluble support resin.

Abstract: An improved punctum plug is more easily visualized when positioned within a punctual canal of a recipient. The body of the plug features an outwardly exposed surface when properly positioned, and a substance causing at least the outwardly exposed surface to contrast with surrounding tissue, such that the use of the substance causes the plug to be more easily visualized than if the substance were not present. The substance, which may be disposed on the outwardly exposed surface or within the body of the plug, may include a saturated coloration, or may be phosphorescent, fluorescent or otherwise operative to reflect or re-radiate light to assist in visualization. For example, the substance may include an organic or inorganic phosphor or fluorescent material, reflective beads, quantum dots, a dye or pigment. Such reflection or re-radiation may occur at the same or different wavelength(s) compared to the illumination wavelength(s), whether or not either or both are within the visible part of the spectrum.

Abstract: Crystalline colloidal arrays (CCA) which have been encapsulated in a polymer matrix to produce more robust polymerized crystalline colloidal arrays (PCCA) are provided. The PCCA's of the present invention can be in the form of a hydrogel which can be compatible for use with a biological system. The polymer matrix of the PCCA is formed of polymerized poly(ethylene glycol) based monomer units which can provide a desired functionality to the PCCA. The PCCA can be formed to exhibit a photonic bandgap at a certain wavelength. The photonic bandgap can be capable of shifting upon some form of environmental stimulation rendering the PCCA suitable for many optical applications, including active photonic switching and sensory applications.

Abstract: A polymeric food spoilage sensor comprises a polymer containing a polyazamacrocyclic transition metal complex. The complex selectively binds biogenic amines, such as cadaverine, putrescine and histamine, which are released by food spoilage microorganisms. The polymer undergoes a detectable color change upon exposure to biogenic amine, thus indicating that food spoilage has probably occurred. In one embodiment, the polymer is molecularly imprinted with the biogenic amine to impart selective binding affinity. The polymer is easily incorporated in common food containers and can be employed in fiber optic detection devices.

Abstract: A polymeric food spoilage sensor comprises a polymer containing a polyazamacrocyclic transition metal complex. The complex selectively binds biogenic amines, such as cadaverine, putrescine and histamine, which are released by food spoilage microorganisms. The polymer undergoes a detectable color change upon exposure to biogenic amine, thus indicating that food spoilage has probably occurred. In one embodiment, the polymer is molecularly imprinted with the biogenic amine to impart selective binding affinity. The polymer is easily incorporated in common food containers and can be employed in fiber optic detection devices.

Abstract: Ingestible compositions comprising a chromic change agent together with methods of making and using them are provided. The chromic change agent alternatively may be associated with the ingestible, such as a packaging material for the ingestible. In response to a triggering event, physical or chemical, the chromic change agent changes color to provide information as to the history of the ingestible, either prior or contemporaneous with use. Depending on the use, the color change agent may be reversible or irreversible. Various solid or liquid ingestible compositions are provided for determining ingestible temperature, storage temperature, user temperature, light exposure, pH change, hydration or solvation change, mechanical stress, and the like, particularly in comestibles. Of particular interest are polydiacetylene polymers that may be formulated to provide compositions having numerous different color transition triggering mechanisms.

Abstract: A toilet system is provided having a receptacle, into which human waste is discharged, the receptacle contains an aqueous disinfectant composition which has an opacifier dispersed therein to reduce the light transmittance of the composition.

Abstract: The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.

Abstract: The instant invention provides a biodegradable tell-tale composition which is applied cutaneously or subcutaneously to a human or animal subject for aiding in the determination of instillation or application of a medicament, vaccine or the like; and furthermore for providing, via the biodegradable functionality, a useful tool for measuring the period of time which has passed since the most recent inoculation.

Abstract: An adhesive cosmetic strip is provided which includes a flexible water-insoluble substrate, an adhesive composition deposited onto the substrate, a liquid crystal thermochromic substance, and an agent interactive with water to ensure a temperature rise of at least 2° C. in the strip. The thermochromic substance may be impregnated into the substrate or dispersed within the adhesive composition. When applied to the skin, the strip is warmed by a reaction between water and an exothermic or endothermic agent held within the strip. Moisture within the skin or externally applied water penetrates the strip and will react with the agent to cause an increase in temperature. Subsequently this increase in temperature will induce a color change in the thermochromic substance.